Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Avantis International Small Cap Value ETF (AVDV) vs AstraZeneca plc (AZN) Price & Performance

Avantis International Small Cap Value ETFTrade
AstraZeneca plcTrade

Price performance (Past 24H)

Key statistics

Avantis International Small Cap Value ETF vs AstraZeneca plc — how do they compare? Avantis International Small Cap Value ETF trades at $110.19, while AstraZeneca plc trades at $158.02 (market cap $248.14B). The key difference: AstraZeneca plc pays a 2.01% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AVDVAZN
Sector
Sector/ThematicHealth
52-Week High
$110.40$209.48
52-Week Low
$83.89$147.06
Market Cap
$248.14B
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Avantis International Small Cap Value ETF

AVDV trades at $110.27, up 0.74% today, with a bullish technical signal from moving averages but caution from oscillators like the 6-day RSI at 87.64 indicating overbought conditions. Recent news highlights strong 2026 performance, with international small-cap value strategies delivering 35% gains and dividends. The fund focuses on cheap, profitable small companies in developed markets outside the U.S., benefiting from diversification and value exposure.

The outlook remains positive due to historical outperformance and dividend yield, but risks include overbought technicals and reliance on global economic stability. Investors should weigh the fund's value approach against potential volatility in international small caps, with support near $108 providing a cushion for pullbacks.

AstraZeneca plc

AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.

Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Avantis International Small Cap Value ETF

AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.

Read more on AVDV

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN